Posted 11 October, 2023

BioNexus Gene Lab Corp appointed new CEO

CEO Change detected for ticker Nasdaq:BGLC in a 8-K filed on 11 October, 2023.

  Departure of Sook Keng Yeoh as Chief Executive Officer and Director.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of BioNexus Gene Lab Corp
Health Care/Life Sciences • Biotechnology
BioNexus Gene Lab Corp. is a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. It is also involved in the development of liquid biopsy tests for the early detection of biomarkers that are linked to diseases. It operates through the BioNexus Malaysia and Chemrex segments. The company was founded on May 12, 2017 and is headquartered in Kuala Lumpur, Malaysia.
Market Cap
View Company Details
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Sook Keng Yeoh as Chief Executive Officer and Director.

On October 4, 2023, Mr. Sook Keng Yeoh, the Chief Executive Officer and a member of the Board of Directors, tendered his resignation letter to Bionexus Gene Lab Corp. (the "Company") from his positions at the Company. The Company and Mr. Sook Keng Yeoh agreed that the resignations would be effective October 4, 2023. Mr. Sook Keng Yeoh's resignation is not due to any disagreement with the Company, the Company's management, or the Board on any matter relating to the Company's operations, policies, or practices (financial or otherwise). 

As a result of this resignation, the Company currently does not have a Chief Executive Officer but is actively identifying such replacement personnel. The Company believes that it will be able to appoint a new CEO in the near future.